CheckmAb Srl is an innovative start-up biotech company focused on the
development of novel monoclonal antibodies for cancer immunotherapy, with the aim to provide safer and more effective therapies for patients.
At present, the company is focused on the development of monoclonal antibodies for cancer immunotherapy, specifically targeting tumor-infiltrating regulatory T lymphocytes. These antibodies are expected to unleash the immunological response only within the neoplastic lesion, thereby avoiding harmful systemic autoimmune reactions that are too often associated with current immuntoherapies.
Company Details
- Employees
- 11
- Founded
- 2018
- Address
- Via Francesco Sforza, 35, Padiglione Romeo Ed Enrica Invernizzi,italy
- Phone
- +39-020-066-0220
- se****@****kmab.eu
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- checkmab.eu
- HQ
- Milan, Lombardy
Checkmab S.r.l. Questions
Checkmab S.R.L.'s helpline number is +39-020-066-0220
Checkmab S.R.L.'s website is checkmab.eu
Checkmab S.R.L.'s LinkedIn profile is https://it.linkedin.com/company/checkmab
Checkmab S.R.L. has
11 employees.
View email and phone details for 11
employees at Checkmab S.R.L..
Checkmab S.R.L.'s industry is
Biotechnology Research
Checkmab S.R.L.'s top competitors are
Genenta Science (Nasdaq: Gnta),
Clepio Biotech,
Genesys Biologics,
Altheia Science,
Resalis Therapeutics,
Prebiomics,
Iama Therapeutics,
Sibylla Biotech,
Alia Therapeutics,
Kither Biotech.
Checkmab S.R.L.'s support email address is segreteria@checkmab.eu
Checkmab S.R.L.'s categories are Biotechnology Research
Checkmab S.R.L.'s founding year is 2018
